Page 8 - 81_03
P. 8
BET inhibitors. The odd compound (+)-JQ1 15. Shao Q, Kannan A, Lin Z, Stack BC, Suen JY, Gao L.
BET protein inhibitor JQ1 attenuates Myc-amplified
Knapp S. Targeting bromodomains: epigenetic readers MCC tumor growth in vivo. Cancer Res 2014; 74:
of lysine acetylation. Nature Rev Drug Discov 2014; 7090-7102.
13: 337-56. (b) Gallenkamp D, Gelato K A, Haendler
B, Weinmann H. Bromodomains and Their 16. Baker EK, Taylos S, Gupte A, et al. BET inhibitors
Pharmacological Inhibitors. ChemMedChem 2014; 9: induce apoptosis through a MYC independent
438-64. (c) Sánchez R, Meslamani J, Zhou MM. The mechanism and synergise with CDK inhibitors to kill
bromodomain: from epigenome reader to druggable osteosarcoma cells. Scientific Reports 2015; 5: Article
target. Biochim Biophys Acta 2014; 1839: 676-85. number 10120.
3. Para una revisión de derivados de diazepina inhibidores 17. Wen S-M, Quan Ch-Y, Jiang N, Shang ZQ, Niu YJ.
de bromodominios ver: Smith SG, Sánchez R, Zhou What is the next generation therapeutic strategy for
MM. Privileged diazepine compounds and their castration-resistant prostate cáncer. Asian J Androl
emergence as bromodomain inhibitors. Chem Biol 2015; 17: 223-24.
2014; 21: 573-83.
18. a) Mirguet O, Gosmini R, Toum J, et al. Discovery of
4. Avendaño C, Menéndez JC. Peptidomimetics in cancer epigenetic regulator I-BET762: lead optimization to
chemotherapy. Clin Transl Oncol 2007; 9: 563-70. afford a clinical candidate inhibitor of the BET
bromodomains. J Med Chem 2013; 56: 7501-15. b)
5. Chung CW, Coste H, White JH, et al. Discovery and Zhao Y, Yang Ch-Y, Wang S. The Making of
characterization of small molecule inhibitors of the I-BET762, a BET Bromodomain Inhibitor Now in
BET family bromodomains. J Med Chem 2011; 54: Clinical Development. J Med Chem 2013; 56: 7498-
3827-38. 7500.
6. Adachi K, Hikawa H, Hamada M, et al. inventors; 19. Boi M, Gaudio E, Bonetti P, et al. The BET
Mitsubishi Tanabe Pharma Corporation, assignee. Bromodomain Inhibitor OTX015 Affects
Thienotriazolodiazepine compound and a medicinal Pathogenetic Pathways in Preclinical B-cell Tumor
use thereof. WO 2006129623 A1. 2006. Sept. Models and Synergizes with Targeted Drugs. Clin
Cancer Res 2015; 21:1628-38.
7. Miyoshi S, Ooike S, Iwata K, Hikawa K, Sugahara K,
inventors; Mitsubishi Tanabe Pharma Corporation, 20. Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition
assignee. Antitumor agent. International patent of BET recruitment to chromatin as an effective
PCT/JP2008/073864. 2009. Sept. treatment for MLL-fusion leukaemia. Nature 2011;
478: 529-33.
8. Filippakopoulos P, Qi PJ, Picaud S, et al. Selective
inhibition of BET bromodomains. Nature 2010; 468: 21. Hewings DS, Wang M, Philpott M, et al. 3,5-
1067-73. Dimethylisoxazoles Act As Acetyl-lysine-mimetic
Bromodomain Ligands. J Med Chem 2011; 54: 6761-
9. Maxmen A. Cancer research: Open ambition. Nature 70.
News & Comment 2012; 488: 148-50.
22. Hewings DS, Fedorov O, Filippakopoulos P, et al.
10. Zuber J, Vakoc C. RNAi screen identifies BRD4 as a Optimization of 3,5-dimethylisoxazole derivatives as
therapeutic target in acute myeloid leukaemia. Nature potent bromodomain ligands. J Med Chem 2013; 56:
2011; 478: 524-28. 3217-27.
11. Delmore JE, Issa GC, Lemieux ME, et al. BET 23. a) Nicodeme E, Jeffrey KL, Schaefer U. Suppression
bromodomain inhibition as a therapeutic strategy to of inflammation by a synthetic histone mimic. Nature
target c-Myc. Cell 2011; 146: 904-17. 2010; 468: 1119-23. b) Toniolo PA, Liu S, Yeh JE, et
al. Inhibiting STAT5 by the BET bromodomain
12. Los inhibidores del proteasoma aumentan los niveles inhibitor JQ1 disrupts human dendritic cell
de proteínas reguladoras, lo que conduce a la muerte maturation. J Immunol 2015; 194: 3180-90.
celular por distintos mecanismos.
24. Para una revisión reciente ver: Kogan P, Wald M. Urol
13. Floyd SR, Pacold ME, Huang Q, et al. The Clin N Am 2014; 41: 145-61.
bromodomain protein BRD4 insulates chromatin from
DNA damage signalling. Nature 2013; 498: 246-50. 25. Matzuk MM, McKeown MR, Filippakopoulos P, et al.
Small-Molecule Inhibition of BRDT for Male
14. a) Raza SS, Knab M, Chow Ch, et al. Development of Contraception. Cell 2012; 150: 673-84.
resistance to BET bromodomain inhibitor JQ1 and
demonstration of epithelial-mesenchymal transition in 26. Palermo RD, Webb HM, West MJ. RNA Polymerase
pancreatic cancer cells. J Clin Oncol 2014; 32 suppl, II Stalling Promotes Nucleosome Occlusion and
e15263. b) Kumar K, Raza SS, Knab LM, et al. GLI2- pTEFb Recruitment to Drive Immortalization by
dependent c-MYC upregulation mediates resistance of Epstein-Barr Virus. PLoS Pathog 2011, 7: e1002334.
pancreatic cancer cells to the BET bromodomain
inhibitor JQ1. Scientific Reports 2015; 5: Article 27. Banerjee C, Archin N, Michaels D, et al. BET
number 9489. c) García PL, Miller AL, Kreitzburg bromodomain inhibition as a novel strategy for
KM, et al. The BET bromodomain inhibitor JQ1 reactivation of HIV-1. Journal of Leukocyte Biology
suppresses growth of pancreatic ductal 2012; 92: 1147-54.
adenocarcinoma in patient-derived xenograft models.
Oncogene 2015; doi:10.1038/onc.2015.126. 219
@Real Academia Nacional de Farmacia. Spain
